Sandoz Completes Coherus Biosimilar Acquisition

Deal For US Cimerli Ranibizumab Rival To Lucentis Closes ‘Ahead Of Anticipated Timelines’

 
• By Dave Wallace

Sandoz has closed its deal to acquire the Cimerli US ranibizumab biosimilar business from Coherus “ahead of anticipated timelines.”

Eyes US flag
Sandoz now has rights to the ophthalmic biosimilar in the US • Source: Shutterstock

More from Deals

More from Business